Notably, human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells highly express CD24, and CD24 knockdown increases the susceptibility of these cells to lapatinib, a HER2 inhibitor [33]. This evidence concerns the gene CD24 and breast carcinoma.